Insider Trading Alert - CYBX, VRX, CSCO, NATI And STI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 20, 2013, 164 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $442.90 to $580,709,873.28.

Highlighted Stocks Traded by Insiders:

Cyberonics (CYBX) - FREE Research Report

Browne Gregory H who is SR VP Finance & CFO at Cyberonics sold 1,500 shares at $61.75 on Nov. 20, 2013. Following this transaction, the SR VP Finance & CFO owned 80,942 shares meaning that the stake was reduced by 1.82% with the 1,500 share transaction.

The shares most recently traded at $65.61, up $3.86, or 5.88% since the insider transaction. Historical insider transactions for Cyberonics go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 22,037
  • 24-Week # shares sold: 62,476

The average volume for Cyberonics has been 200,800 shares per day over the past 30 days. Cyberonics has a market cap of $1.7 billion and is part of the health care sector and health services industry. Shares are up 17.88% year to date as of the close of trading on Wednesday.

Cyberonics, Inc., together with its subsidiaries, engages in the design, development, marketing, and sale of implantable medical devices to hospitals and ambulatory surgery centers. The company has a P/E ratio of 36.9. Currently there are 6 analysts that rate Cyberonics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CYBX - FREE

TheStreet Quant Ratings rates Cyberonics as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Cyberonics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Valeant Pharmaceuticals International (VRX) - FREE Research Report

Kornwasser Laizer who is EVP, Company Group Chairman at Valeant Pharmaceuticals International bought 3,500 shares at $107.38 on Nov. 20, 2013. Following this transaction, the EVP, Company Group Chairman owned 16,500 shares meaning that the stake was reduced by 26.92% with the 3,500 share transaction.

The shares most recently traded at $108.23, up $0.85, or 0.78% since the insider transaction. Historical insider transactions for Valeant Pharmaceuticals International go as follows:

  • 4-Week # shares bought: 1,500
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 53,500
  • 12-Week # shares sold: 14,000
  • 24-Week # shares bought: 71,972
  • 24-Week # shares sold: 20,000

The average volume for Valeant Pharmaceuticals International has been 1.1 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $35.4 billion and is part of the health care sector and drugs industry. Shares are up 78.28% year to date as of the close of trading on Wednesday.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. The stock currently has a dividend yield of 0.95%. Currently there are 8 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRX - FREE

TheStreet Quant Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Cisco Systems (CSCO) - FREE Research Report

Patel Pankaj who is EVP, Chief Development Officer at Cisco Systems sold 50,000 shares at $21.64 on Nov. 20, 2013. Following this transaction, the EVP, Chief Development Officer owned 211,643 shares meaning that the stake was reduced by 19.11% with the 50,000 share transaction.

The shares most recently traded at $21.37, down $0.27, or 1.27% since the insider transaction. Historical insider transactions for Cisco Systems go as follows:

  • 12-Week # shares sold: 209,824
  • 24-Week # shares sold: 306,854

The average volume for Cisco Systems has been 41.0 million shares per day over the past 30 days. Cisco Systems has a market cap of $115.3 billion and is part of the technology sector and computer hardware industry. Shares are up 9.01% year to date as of the close of trading on Wednesday.

Cisco Systems, Inc. designs, manufactures, and sells Internet protocol (IP) and other products related to the communications and information technology industry worldwide. The stock currently has a dividend yield of 3.17%. The company has a P/E ratio of 11.6. Currently there are 19 analysts that rate Cisco Systems a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CSCO - FREE

TheStreet Quant Ratings rates Cisco Systems as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Cisco Systems Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

National Instruments Corporation (NATI) - FREE Research Report

Kodosky Jeffrey L who is Director at National Instruments Corporation sold 12,000 shares at $31.86 on Nov. 20, 2013. Following this transaction, the Director owned 995,180 shares meaning that the stake was reduced by 1.19% with the 12,000 share transaction.

The shares most recently traded at $31.19, down $0.67, or 2.16% since the insider transaction. Historical insider transactions for National Instruments Corporation go as follows:

  • 4-Week # shares sold: 15,016
  • 12-Week # shares sold: 47,016
  • 24-Week # shares sold: 99,016

The average volume for National Instruments Corporation has been 420,100 shares per day over the past 30 days. National Instruments Corporation has a market cap of $3.9 billion and is part of the technology sector and computer software & services industry. Shares are up 21.74% year to date as of the close of trading on Wednesday.

National Instruments Corporation designs, manufactures, and sells tools to engineers and scientists worldwide. It offers LabVIEW, a system design software product for measurement and control; and LabVIEW Real-Time and LabVIEW FPGA that are strategic modular software add-ons. The stock currently has a dividend yield of 1.78%. The company has a P/E ratio of 57.1. Currently there is 1 analyst that rates National Instruments Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NATI - FREE

TheStreet Quant Ratings rates National Instruments Corporation as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full National Instruments Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

SunTrust Banks (STI) - FREE Research Report

Panther Thomas E who is SVP, Controller, CAO at SunTrust Banks sold 1,351 shares at $36.12 on Nov. 20, 2013. Following this transaction, the SVP, Controller, CAO owned 37,073 shares meaning that the stake was reduced by 3.52% with the 1,351 share transaction.

The shares most recently traded at $35.99, down $0.13, or 0.36% since the insider transaction. Historical insider transactions for SunTrust Banks go as follows:

  • 4-Week # shares bought: 20,000
  • 12-Week # shares bought: 20,000
  • 12-Week # shares sold: 18,644
  • 24-Week # shares bought: 20,000
  • 24-Week # shares sold: 21,144

The average volume for SunTrust Banks has been 3.7 million shares per day over the past 30 days. SunTrust Banks has a market cap of $19.2 billion and is part of the financial sector and banking industry. Shares are up 26.38% year to date as of the close of trading on Wednesday.

SunTrust Banks, Inc. operates as the holding company for SunTrust Bank that provides various financial services in the United States. The company operates in three segments: Consumer Banking and Private Wealth Management, Wholesale Banking, and Mortgage Banking. The stock currently has a dividend yield of 1.12%. The company has a P/E ratio of 15.4. Currently there are 8 analysts that rate SunTrust Banks a buy, 3 analysts rate it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STI - FREE

TheStreet Quant Ratings rates SunTrust Banks as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full SunTrust Banks Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices